Vladonix
Research OnlyA cytamin-class peptide supplement derived from thymus tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for immune support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Thymus cytamin · Thymic peptide supplement · A-19 thymus peptides
Mostly preclinical · 1 human study
- Preclinical
- 75%
- Clinical
- 13%
Based on 8 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 26 (1A 13 / 1B 4 / 1C 2 / 1D 3 / 1E 4): best human evidence for Vladonix itself is uncontrolled Russian observational immune-marker data in elderly subjects (high RoB, total human N likely <50); the stronger human signal belongs to the injectable thymus analogue thymalin (33575961 COVID-19 adjunct, 33237528 HSC differentiation), so it is indirect to this undefined oral cytamin with poor peptide bioavailability; modest multi-model preclinical base for the class. Mechanism 35 (2A 10 / 2B 10 / 2C 7 / 2D 8): Khavinson short-peptide gene-regulation framework (12374906) is characterized for DEFINED peptides, but Vladonix is an undefined tissue mixture so target is inferred, not bound; proximal T-cell/cytokine signaling partly mapped and dose-response shown for related thymalin/tinrostim in vivo (24734422). Plausibility 62 (3A 18 / 3B 19 / 3C 14 / 3D 11): mechanism->immune-marker surrogate is coherent with thymic biology, but the oral-bioavailability link is an unproven intermediate; same-class agents (thymalin, thymosin alpha-1) show analogous immune effects (analogy support); claim is moderately scoped to immune support. Global Coverage 36 (4A 12 / 4B 10 / 4C 9 / 4D 5): replication concentrated in the St. Petersburg/Khavinson group with limited independent work (Ukraine 11758469, Vladivostok 24734422); class literature ~5-20 studies; available in Russia as a supplement, no regulator drug approval. Community Experience 18 (5A 4 / 5B 5 / 5C 3 / 5D 6): dossier documents no meaningful community discussion or user reports; no recurring adverse signal but exposure is minimal (not proof of safety). Overall 35 = round(0.30*26 + 0.20*35 + 0.20*62 + 0.15*36 + 0.15*18) -> preliminary. Effectiveness not established: no quantified human efficacy estimate for Vladonix and no meaningful community effect signal (precedence Clinical -> Community-reported -> Not Established).
Mechanism of Action
Vladonix is a cytamin-class supplement containing peptide complexes derived from thymus tissue.
Cytamin Classification
Cytamins are oral peptide supplements in the Russian bioregulator framework, distinct from injectable bioregulators:
- Derived from animal tissue extracts
- Contain multiple peptide fractions
- Marketed as dietary supplements
- Not single defined compounds
Proposed Mechanisms
- Thymic Support - Claimed to support T-cell maturation via peptide signaling
- Immune Modulation - Proposed effects on immune cell function
- Age-Related Decline - Marketed to address thymic involution
Important Limitations
- NOT a defined single peptide - contains complex mixture
- No Western clinical validation
- Oral bioavailability of peptides generally very low
- No randomized controlled trials
- Not approved by any Western regulatory agency
Thymalin
CompatibleBoth target thymus function - Thymalin is injectable extract, Vladonix is oral cytamin supplement. May have overlapping mechanisms.
Vilon
CompatibleBoth target thymic function - Vilon is synthetic dipeptide, Vladonix is tissue-derived complex.
Thymosin-Alpha-1
CompatibleBoth target immune function but different origins - Ta1 is defined 28-AA peptide with FDA orphan status, Vladonix is Russian cytamin supplement.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Vladonix
Related Peptides
Alpha-Defensins
HNP-1 · HNP-2 · HNP-3 +5
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) +1
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG · Glu-Asp-Gly · Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin · hCAP18 · Human Cationic Antimicrobial Peptide 18 +3
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.